We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular for prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol (2020) 203(1):73-82. PMID: 31389764
The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res (2017) 23(17):5112-5122. PMID: 28615267
DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet (2015) 15;24(4):963-71. PMID: 25281662
Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 232(5):566-77. PMID: 24407904
I have set up a research team devoted to cancer genetic studies and biomarker development, in particular in male urological cancers. The mission of the research team is to reduce mortality and morbidity of cancer patients by understanding cancer development and progression mechanisms and facilitating precision medicine through the development of efficient cancer detection, prognostic and treatment response prediction/monitoring biomarkers.
Our past work has been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, including CTCs, exosome and other cells, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.
There are currently two main research areas of interest:
Differential cross-section measurements for the electroweak production of dijets in association with a Z boson in proton–proton collisions at ATLAS Aad G, Abbott B, Abbott DC et al. European Physical Journal C (2021) 81(7)
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Conti DV, Darst BF, Moss LC et al. Nat Genet (2021) (2)
The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing Guo T, Wang Y, Jia J et al. Frontiers in Cell and Developmental Biology (2021) 8(7)
The transcriptomic landscape of prostate cancer development and progression: An integrative analysis Marzec J, Ross-Adams H, Pirrò S et al. Cancers (2021) 13(7) 1-24
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction Conti DV, Darst BF, Moss LC et al. Nature Genetics (2021) 53(7) 65-75
An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk Wu L, Yang Y, Guo X et al. Nature Communications (2020) 11(7)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (Nature Communications, (2020), 11, 1, (4748), 10.1038/s41467-020-18151-y) Bailey MH, Meyerson WU, Dursi LJ et al. Nature Communications (2020) 11(7)
Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan Hollis B, Day FR, Busch AS et al. Nature Communications (2020) 11(7)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples Bailey MH, Meyerson WU, Dursi LJ et al. Nature Communications (2020) 11(7)
Sex differences in oncogenic mutational processes Li CH, Prokopec SD, Sun RX et al. Nature Communications (2020) 11(7)For additional publications, please click here
Xueying Mao, Elzbieta Stankiewicz
Tanyu Guo, Caitlin Davis, Yeuzhou Zhang